the preclinical data in crizotinib means little at this point considering the remarkable effects it has had in humans. do you really think that pfizer doesnt know which target its hitting at this point, lol? clearly, all the preclinical and clinical evidence points directly to a ALK positive patient having a dramatic effect on the drug.
im not sure i am really following your post.
the entire scientific community doesnt have it wrong.
Market Data 
Markets 
AI
